Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

Share this content:
Reports on the efficacy of VEGF–tyrosine kinase inhibitors as adjuvant therapies for patients with RCC have been mixed.
Reports on the efficacy of VEGF–tyrosine kinase inhibitors as adjuvant therapies for patients with RCC have been mixed.

This article originally appeared in Cancer Therapy Advisor.

Adjuvant sunitinib postnephrectomy may increase the mortality risk among older women with renal cell cancer (RCC), according to a study being presented at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California.

Studies investigating the safety and efficacy of VEGF–tyrosine kinase inhibitors (TKIs) as adjuvant therapies for patients with RCC have yielded mixed results.

For the phase 3 ASSURE (E2805) study (ClinicalTrials.gov Identifier: NCT00326898), 1943 patients with resected RCC were randomly assigned to treatment with sunitinib, sorafenib, or placebo. Previous findings suggested that there were no benefits to overall survival (OS) or disease-free survival (DFS) with VEGF-TKIs vs placebo. For this post hoc subgroup analysis, researchers assessed the associations between benefit, sex, and age.

Women older than 56 years treated with sunitinib had an increased mortality risk compared with those who received placebo (hazard ratio for OS [HR], 2.38; 95% CI, 1.39-4.07). This risk was not found among women younger than 56 or men of any age.

Women older than 56 years also had an increased risk of disease recurrence when treated with sunitinib vs placebo (HR for DFS, 1.53; 95% CI, 1.03-2.28).

No significant differences in OS or DFS were observed with sorafenib and placebo.

The authors concluded that these “findings, if validated, highlight the importance of considering sex and age on VEGF-TKI treatment outcomes, future study designs, and RCC tumor biology.”

Reference

Mamtani R, Wang XV, DiPaola RS, Dutcher JP, Haas NB. Association of age and sex with mortality following adjuvant therapy for renal cell cancer (RCC): subgroup analysis of the ASSURE (E2805) trial. Oral presentation at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs